Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

BACKGROUND: The Ebola epidemics in west Africa and the Democratic Republic of the Congo highlight an urgent need for safe and effective vaccines to prevent Ebola virus disease. We aimed to assess the safety and long-term immunogenicity of a two-dose heterologous vaccine regimen, comprising the adeno...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Infect Dis
Autori principali: Ishola, David, Manno, Daniela, Afolabi, Muhammed O, Keshinro, Babajide, Bockstal, Viki, Rogers, Baimba, Owusu-Kyei, Kwabena, Serry-Bangura, Alimamy, Swaray, Ibrahim, Lowe, Brett, Kowuor, Dickens, Baiden, Frank, Mooney, Thomas, Smout, Elizabeth, Köhn, Brian, Otieno, Godfrey T, Jusu, Morrison, Foster, Julie, Samai, Mohamed, Deen, Gibrilla Fadlu, Larson, Heidi, Lees, Shelley, Goldstein, Neil, Gallagher, Katherine E, Gaddah, Auguste, Heerwegh, Dirk, Callendret, Benoit, Luhn, Kerstin, Robinson, Cynthia, Leyssen, Maarten, Greenwood, Brian, Douoguih, Macaya, Leigh, Bailah, Watson-Jones, Deborah
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2022
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7613326/
https://ncbi.nlm.nih.gov/pubmed/34529963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(21)00125-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi